PHARMA SOLUTIONS
NASH & NAFLD
We offer a turn-key medical imaging solution for clinical trials in nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD). Our robust, quantitative biomarkers and artificial intelligence-driven digital pathology services provide standardized insight into patient health.
Metrics
Liver Fat (MRI-PDFF)
Liver Stiffness (MRE)
Digital Pathology
Clinical research opportunity
Multi-organ characterization for comprehensive assessment of patient health
Expert central reads of quantitative metrics using our platform-based services for:
Liver, kidneys, pancreas, spleen, heart, aorta, biliary tree, colon, body composition, and bone mineral density.
Imaging Technologies include:
MRI, computerised tomography (CT), positron emission tomography (PET), DXA, endoscopy, and digital pathology.
Standardized and reproducible results
Our biomarkers have excellent reproducibility and repeatability (7) with diagnostic accuracy that is superior to others. This enables more reliable monitoring of disease progression as a response to treatment and allows smaller trials to be run with more confidence. (19,20,21)
Our proprietary technology corrects for iron content, field strength, and manufacturer differences to deliver a “corrected T1” or cT1. This allows more robust metrics to be collected, thereby supporting multi-site trials.
References
1. Banerjee, R., et al. (2014). J Hepatol, 60(1), 69-77.
2. Pavlides, M., et al. (2016). J Hepatol, 64(2), 308-315.
3. Pavlides, M., et al. (2017). Liver Int, 37(7), 1065-1073.
4. Idilman, I. S., et al. (2013). Radiology, 267(3), 767–775.
5. Caussy, C., et al. (2018). Hepatology, 68(2), 763–772.
6. Wilman, H.R., et al. (2017). PLOS ONE, 12(2), e0172921.
7. Bachtiar, V., et al. (2019). PLOS ONE, 14(4), e0214921.
8. McDonald, N., et al. (2018). Sci Rep, 8(1), 9189.
9. Mayo R., et al. (2018). Hepatol Commun, 2(7), 807–20.
10. Wildman-Tobriner, B., et al. (2018). Gastroenterology, 155(5), 1428–1435.
11. Park, C. C., et al. (2017). Gastroenterology, 152(3), 598–607.
12. Jayaswal, A., et al. (2020). Liver International, 40(12), 3071-3082.
13. Dennis, A., et al. (2020). Scientific Reports, 10(1), 15308.
14. Imajo, K., et al. (2021). World Journal of Gastroenterology, 27(7), 609–623.
15. Dennis, A., et al. (2021). Frontiers in Endocrinology, 11, 575843.
16. Beyer, C., et al. (2021). Plos One, 16(4), e0249491.
17. Andersson, A., et al. (2021). Clinical Gastroenterology and Hepatology, S1542-3565(21)01056-9.
18. Harrison, S., et al. (2018). PloS One, 13(9), e0203054.
19. Harrison, S.A. et al. (2020). Journal of Hepatology, 71(4), 1198–1212.
20. Harrison, S.A., et al. (2021). The American Journal of Gastroenterology. 10.14309/ajg.0000000000001375
21. Langford, C.R., et al. (2021). Journal of Clinical Pathology. 75(2), 73–75.
These products and services are for investigational use only.